TNF Pharmaceuticals, Inc.
TNFA
$0.1416
$0.00463.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -12.26% | -5.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.92% | 19.90% | |||
| Operating Income | -12.92% | -19.90% | |||
| Income Before Tax | 45.52% | -6.99% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 45.52% | -6.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 45.52% | -6.99% | |||
| EBIT | -12.92% | -19.90% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 66.78% | 1.73% | |||
| Normalized Basic EPS | 70.65% | 14.91% | |||
| EPS Diluted | 66.78% | 1.74% | |||
| Normalized Diluted EPS | 70.65% | 14.91% | |||
| Average Basic Shares Outstanding | 86.07% | 19.05% | |||
| Average Diluted Shares Outstanding | 86.07% | 19.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||